Cancer Development: Below Is A List of Topics Covered in This Section
Cancer Development: Below Is A List of Topics Covered in This Section
Cancer Development: Below Is A List of Topics Covered in This Section
CancerDevelopment.jpg
Introduction
Simply put, cancer is the result of unregulated cell division. Cancer cells divide when they are not supposed to,
don't stop dividing when they are supposed to and don't die when they should. In the worst cases, the cancer
cells leave the area in which they arose and travel to other parts of the body.
Cancer cells do not look or act like the normal cells from which they originate. It is reasonable, then, to ask 'Why
do cancer cells behave so badly?'. It turns out the the answers lie in the genes of the affected cells. In cancer cells,
changes to key genes cause the cells to act abnormally. The changes are often the result of changes to the DNA
(mutations) in the cells. Because there are many different things that are capable of causing mutation, there are
an equally large number of causes of cancer.
The development of cancer takes place in a multi-step process. As the cells become more abnormal, they gain new
capabilities, such as the ability to release growth factors and digestive enzymes. The cells continue to divide,
impacting nearby normal cells, often reducing the function of the affected organ. Even abnormal cancer cells die
sometime and a tumor that is large enough to feel can take years to reach that size. Although not all cancers share
exactly the same steps, there are some general features that are shared in the development of many types of
cancer. Further information on the topics on this [ ]
page can also be found in most introductory Biology textbooks,
we recommend Campbell Biology, 11th edition. 1
The initial experimental studies of carcinogenesis were conducted in animals. Chemicals able to react with DNA
and non-reactive compounds were both tested for their ability to cause cancer. The model used was mouse skin
carcinogenesis. In this system researchers painted test chemicals on the skin and observed the growth of tumors.
Researchers found that application of a DNA reactive substance only resulted in tumor formation when the
animals were further treated with another non-reactive substance. A compound that reacts with DNA and
somehow changes the genetic makeup of the cell is called a mutagen. The mutagens that predispose cells to
develop tumors are called initiators and the non-reactive compounds that stimulate tumor development are[ ]
called promoters. Approximately 70% of known mutagens are also carcinogens--cancer-causing compounds. 3 A
compound that acts as both an initiator and a promoter is referred to as[ a] 'complete carcinogen' because tumor
development can occur without the application of another compound. 4
Initiation
Initiation is the first step in the two-stage model of cancer development. Initiators, if not already reactive with
DNA, are altered (frequently they are made electrophilic) via drug-metabolizing enzymes in the body and are then
[ ]
able to cause changes in DNA (mutations). 4 Since many initiators must be metabolized before becoming active,
[ 5]
[ ]
initiators are often specific to particular tissue types or species. 5 The effects of initiators are irreversible; once a
particular cell has been affected by an initiator it is susceptible to promotion until its death. Since initiation is
the result of permanent genetic change, any daughter cells produced from the division of the mutated cell will
[ ]
also carry the mutation. 4 In studies of mouse skin carcinogenesis, a linear relationship has been observed
between the dose of initiator and the quantity of tumors that can be produced, thus any exposure to the initiator
[ ]
increases risk and this risk increases indefinitely with higher levels of exposure. 5
Promotion
Once a cell has been mutated by an initiator, it is susceptible to the effects of promoters. These compounds
promote the proliferation of the cell, giving rise to a large number of daughter cells containing the mutation
[ ]
created by the initiator. 6 Promoters have no effect when the organism in question has not been previously
[ ]
treated with an initiator. 5
Unlike initiators, promoters do not covalently bind to DNA or macromolecules within the cell. Many bind to[ ]
receptors on the cell surface in order to affect intracellular pathways that lead to increased cell proliferation. 4
There are two general categories of promoters: specific promoters that interact with receptors on or in target cells
of defined tissues and nonspecific promoters that alter gene expression without the presence of a known
receptor. Promoters are often specific for a particular tissue or species due to their interaction with receptors that
are present in different amounts in different tissue types.
While the risk of tumor growth with promoter application is dose-dependent, there is both a threshold and a
maximum effect of promoters. Very low doses of promoters will not lead to tumor development and extremely
[ ]
high doses will not produce more risk than moderate levels of exposure. 5
Progression
In mice, repeated promoter applications on initiator-exposed skin produces benign papillomas. Most of these
papillomas regress after treatment is stopped, but some progress to cancer. The frequency of progression suggests
[ ]
that the papillomas that progress to cancer have acquired an additional, spontaneous, mutation. 7 The term
progression, coined by Leslie Foulds, refers to the stepwise transformation of a benign tumor to a neoplasm and
to malignancy. Progression is associated with a karyotypic change since virtually all tumors that advance are
aneuploid (have the wrong number of chromosomes). This karyotypic change is coupled [with ]
an increased
growth rate, invasiveness, metastasis and an alteration in biochemistry and morphology. 5
Hyperplasia- The altered cell divides in an uncontrolled manner leading to an excess of cells in that region of the
tissue. The cells have a normal appearance but there are too many of them!
Dysplasia- Additional genetic changes in the hyperplastic cells lead to increasingly abnormal growth. The cells
and the the tissue no longer look normal. The cells and the tissue may become disorganized.
Carcinoma in situ- Additional changes make the cells and tissues appear even more abnormal. The cells are now
spread over a larger area and the region of the tissue involved primarily contains altered cells. The cells often
'regress' or become more primitive in their capabilities. An example would be a liver cell that no longer makes
liver-specific proteins. Cells of this type are said to be de-differentiated or anaplastic. A key facet of in situ growths
is that the cells are contained within the initial location and have not yet crossed the basal lamina to invade other
tissues. Cancers of this type are often totally curable by surgery since the abnormal cells are all in one location.
Tumors of this type have not yet invaded neighboring tissue. Based on information about patients with similar
growths and microscopic examination, these growths are often considered to have the potential to become
invasive and are treated as malignant growths.
Cancer (Malignant tumors)- These tumors have the ability to invade surrounding tissues and/or spread
(metastasize) to areas outside the local tissue. These metastatic tumors are the most dangerous and account for a
large percentage of cancer deaths. The next few sections will go into some detail on the changes and capabilities
that allow cancer cells to form large tumors and to metastasize to other parts of the body.
Some tumors do not progress to the point where they invade distant tissues. Such tumors are said to be benign.
Because they do not spread beyond their initial location, they are not considered to be cancerous. Benign tumors
are less often lethal than malignant tumors, but they can still cause serious health problems. Large benign tumors
can put pressure on organs and cause other problems. In the case of brain tumors, the limited space within the
skull means that a large growth in the brain cavity can be fatal.
More information on this topic may be found in Chapters 13 and 14 of The Biology of Cancer by Robert A.
Weinberg.
In most parts of the body, stem cells are not very active. In some locations, including the gastrointestinal tract,
stem cells divide and differentiate constantly to replace cells that are shed or die. Stem cells also play a role in
healing damaged tissue.
Below is a video of the process by which stem cells can accomplish both self-renewal and differentiation. The [ ]
process is called "asymmetric cell division," and it assures that stem cells are always available when needed. 8
The probability of any particular cell developing a set of mutations that leads to cancer is relatively low. The cells
types that are affected by the majority of cancers, epithelial cells, have short lives and are even less likely to
accumulate all the mutations they need. Normal stem cells, which are long-lived, are more likely to be [ ]
around long
enough to accumulate the necessary mutations and are a good possible source of cancer stem cells. 8
What is the difference between the cancer stem cell hypothesis of the origin of cancer and traditional views on the
origin of cancer?
The cancer stem cell hypothesis suggests that only a small portion of cells are capable of becoming cancerous. In
other words, only a small population of cells in a tumor is responsible for the continuous, uncontrolled growth
seen in cancer.
The traditional views on the origin of cancer predict that any cell is able to acquire mutations that lead to
uncontrolled
[ ]
reproduction. Likewise, all of the cells in a tumor would be predicted to be able to divide
endlessly. 9
One of the pieces of evidence that favors the existence of cancer stem cells is the fact that when researchers look
at tumors they appear to contain several differentiated cell types. The traditional theory on the development of
cancer is able to explain this, but the large number of mutations necessary to create the mixture is unlikely. An
illustration,- if tumors form from a single mutated cell the tumor would only contain cells of that type rather than
cells of many types:
If multiple cells of different types in the same area have mutations this would lead to a tumor of mixed cell types:
Cancer stem cells have the ability to produce cells of many different types creating the mixture of cells found in a
tumor:
The possibility of a stem cell becoming a cancer stem cell is, statistically, more likely to happen than multiple
[ ][ ]
mutations in multiple cells in the same area in order to produce a tumor with multiple cell types. 11 9
A potential cancer drug, napabucasin, has been found to target 'stemness.' According to two separate studies, a
treatment
[ ]
combining napabucasin with chemotherapy was able to block STAT3 gene transcription in cancer stem
cells. 13 Napabucasin was shown to kill colorectal stem cells, block their renewal, and kill cancer
[ ]
cells 14[ ]Napabucasin could have serious side effects in humans, as it has been shown to cause bone loss in
mice. 15
All of our cells have similar structures and share a majority of their functions.
Cancers may be categorized into five basic types based on the cell of origin:
Carcinoma - epithelial cells
Sarcoma - muscle, bone, cartilage, fat, or connective tissue
Leukemia - blood cells or their precursors
Lymphoma - bone marrow derived cells; cancer affects the lymphatic system
Myeloma - specific blood cells; B lymphocytes (B-cells)
Carcinogens
Certain viruses and bacteria have also been associated with the initiation and promotion of tumor growth.
Some viruses cause cancer directly by affecting cell division while other viruses cause cancer by causing
chronic inflammation or reducing immune system function.
Chronic Inflammation
1. Urry, L. A., Cain, M. L., Wasserman, S. A., Minorsky, P. V., & Reece, J. B. (2017). Campbell Biology (11th ed.). Pearson.
2. Weinberg, RA. "Finding the Anti-Oncogene." Scientific American (1988). 259(3): 44-51. [PUBMED]
3. Yamagiwa K, Ichikawa K. Experimental Study of the Pathogenesis of Carcinoma. J Cancer Res 3:1-29 (1918).
[http://caonline.amcancersoc.org/cgi/content/abstract/27/3/174]
a. b. c. d.
4. Troll W, Wiesner R. The role of oxygen radicals as a possible mechanism of tumor promotion. Annu Rev Pharmacol Toxicol. 1985;25:509-28. [PUBMED]
5. a. b. c. d. e. Pitot, H.C., Goldsworthy, T., Moran, S. The natural history of carcinogenesis: Implications of experimental carcinogenesis in the genesis of human cancer.
Journal of Supramolecular Structure and Cellular Biochemistry; Volume 17, Issue 2 , Pages 133 146. Published Online: 19 Feb 2004.
6. Yamagiwa K, Ichikawa K. Experimental Study of the Pathogenesis of Carcinoma. J Cancer Res 3:1-29 (1918).
[http://caonline.amcancersoc.org/cgi/content/abstract/27/3/174]
7. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. Molecular Biology of the Cell; Fourth Edition. 23. Cancer. Garland Science; NY. 2002.
a. b. c.
8. Mackenzie IC. "Cancer Stem Cells" Annals of Oncology. 2008 Jul;19 Suppl 5:v40-3. [PUBMED]
9. a. b. c. d. Boman BM, Wicha MS. "Cancer Stem Cells: A Step Toward the Cure" Journal of Clinical Oncology. 2008 Jun 10;26(17):2795-9. [PUBMED]
10. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. "Induced Pluripotent Stem Cells Generated Without Viral Integration." Science. 2008 Sep 25.
[PUBMED]
Lee CJ, Dosch J, Simeone DM. "Pancreatic Cancer Stem Cells." Journal of Clinical Oncology (2008); 26(17):2806-12 [PUBMED]
11. a. b.
12. Pan CX, Zhu W, Cheng L. "Implications of cancer stem cells in the treatment of cancer." Future Oncology. 2006 Dec;2(6):723-31. [PUBMED]
13. Powers, Virginia. "Napabucasin Clinically Active in Both Pancreatic and Colon Cancer." OncLive (2017). [ONCLIVE]
14. BH O'Neil, et al. "LBA-003 Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic
colorectal cancer (mCRC) patients (pts)." Annals of Oncology (2017). [ANN ONCOL]
15. Huang, X., Jin, A., Wang, X., Gao, X., Xu, H., Chung, M., et al. (2021). Napabucasin Induces Mouse Bone Loss by Impairing Bone Formation via STAT3. Frontiers In
Cell And Developmental Biology, 9, 648866. http://doi.org/10.3389/fcell.2021.648866 [PUBMED]